同源框基因NKX3.1 mRNA和蛋白在前列腺组织特异性表达及与前列腺癌关系的探讨

目的:分析同源框基因NKX3.1 mRNA和蛋白在国人前列腺组织表达状况以及与前列腺癌关系。方法:采用半定量RT-PCR、蛋白杂交和免疫组化检测76例前列腺组织、96例非前列腺组织标本NKX3.1 mRNA和蛋白表达状况。结果:RT-PCR检测显示76例前列腺组织NKX3.1 mRNA表达率98.7%,96例非前列腺组织标本中,除2例睾丸组织、1例乳腺组织有NKX 3.1表达外,其余肾脏、膀胱、肝脏、回肠、脂肪、皮肤组织无1例表达(P<0.01)。蛋白杂交显示NKX 3.1蛋白总阳性表达率前列腺组织为100%,睾丸、乳腺组织均为16.7%,膀胱、回肠组织为8.3%,其他肾脏、肝脏、脂肪和皮肤组织均为0(P<0.01)。免疫组化检测显示NKX3.1蛋白主要分布在前列腺上皮细胞,上皮细胞总阳性表达率为94.7%,间质细胞NKX3.1蛋白总阳性表达率为5.3%;NKX3.1蛋白强阳性表达率良性前列腺组织为13.6%,前列腺癌组为40.6%(P<0.01)。结论:NKX3.1基因不仅为前列腺器官特异性基因,并且可能是前列腺腺上皮细胞特异性基因,其表达与前列腺癌关系密切。

The Specific Expression Profile of Homeobox Gene NKX3.1 mRNA and Protein in Prostate Tissues and Its Relationship with Primary Prostate Cancer

Objective: To determine expressions of NKX3.1 mRNA and protein in prostatic tissues and to investigate the relation between homeobox gene NKX3.1 and prostatic carcinoma. Methods: 76 prostatic tissues(32 cancer,12 normal prostate and 32 benign prostatic hyperplasia tissues) and 96 non-prostatic tissues were analyzed for the detection of expressions of NKX3.1 mRNA and protein by using semi-quantitative RT-PCR,Western blotting and immunohistochemical technique. Results: In 76 prostatic tissues,NKX3.1 mRNA was detected in 75 specimens((98.7)%),whereas in 96 non-prostatic specimens,NKX3.1 mRNA was negatively expressed in the tissues of bladder,kidney,liver,intestine,fat and skin,except for two expressed in testis and one in mammary gland.The expression ratio of NKX3.1 protein in the epithelia cells of prostate was 100%,but in testis mammary gland was(16.7)%,in bladder and intestine was(8.3)%,and in kidney,liver,fat and skin was 0%(P<(0.01)).The total strong positive ratio of NKX3.1 protein in the epithelia cell of prostate was(94.7)%,(5.3)% in the stroma cell of prostate(P<(0.01)),and(13.6)% in benignant prostate cell,(40.6)% in prostate cancer(P<(0.01)),respectively.Conclusion: It is suggested that NKX3.1 is not only the prostate-specific homeobox gene,but is the epithelia-cell-specific gene of prostate.It may play an important role in the development of prostatic carcinoma. Natl J Androl,2006,12(2):137-140,144